Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Crinetics Pharmaceuticals Inc chart...

About the Company

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

$34M

Total Revenue

194

Employees

$3B

Market Capitalization

-12.12

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CRNX News

Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions

2h ago, source: Pharmaceutical Technology

Discover how Crinetics Pharmaceuticals Inc's patent for compounds modulating somatostatin activity can suppress hormone secretion in mammals. Explore the detailed framework for hormone modulation and ...

Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares

8d ago, source:

Marc Wilson, Chief Financial Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), has sold 6,942 shares of the company on ...

Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why

on MSN ago, source:

Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically ...

Insiders Are Dumping These 5 Healthcare Stocks

1d ago, source:

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is a clinical stage biopharma company that is working on treatments for endocrine ...

Crinetics gains as late-stage trial for lead drug succeeds

10d ago, source: Seeking Alpha on MSN

Crinetics Pharmaceuticals (NASDAQ:CRNX) added ~12% premarket Tuesday after its second Phase 3 trial for lead asset ...

Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Results

8d ago, source:

Crinetics Pharmaceuticals (CRNX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 19.

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

10d ago, source:

Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated ...

Crinetics' hormonal disorder drug succeeds in late-stage study

10d ago, source:

Crinetics Pharmaceuticals said on Tuesday its experimental drug to treat a rare hormonal disorder met the main goal of the ...

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

9d ago, source: Zacks.com on MSN

Crinetics Pharmaceuticals, Inc. (CRNX) shares ended the last trading session 19.1% higher at $45.18. The jump came on an impressive volume with a higher-than-average number of shares changing hands in ...

Crinetics Pharmaceuticals Earns ‘Buy’ Rating on Clinical Success and Market Expansion Potential

14d ago, source:

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) on March 13 and ...

Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission

9d ago, source: BioSpace

The biotech Tuesday reported that 56% of patients taking paltusotine in a late-stage trial achieved the primary endpoint of ...

Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...

6d ago, source: Yahoo Finance

Chief Medical and Development Officer Dana Pizzuti of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 15,089 shares of the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...